Insys Therapeutics Inc (INSY):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Insys Therapeutics Inc (INSY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9766
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:61
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Insys Therapeutics Inc (Insys) is a specialty pharmaceutical company, which discovers, develops and commercializes novel drug delivery systems of therapeutic compounds. The company harnesses its proprietary sublingual spray technology to develop pharmaceutical cannabinoids. Its flagship product, Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP). Its lead product candidate, Syndros (dronabinol oral solution), is intended for the treatment of chemotherapy-induced nausea and vomiting (CINV) and anorexia associated with weight loss in AIDS patients. The company offers its products to oncologists, pain specialists and supportive care centers for the potential treatment of addiction to opioids, opioid overdose and epilepsy. It has operations in the US and offers its products in international markets. Insys is headquartered in Chandler, Arizona, the US.

Insys Therapeutics Inc (INSY) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Insys Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Insys Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
INSYS Therapeutics Expands Agreement with University of California San Diego 12
Licensing Agreements 13
INSYS Therapeutics Enters into Licensing Agreement with Lunatus 13
Insys Therapeutics Enters into Licensing Agreement with Senzer 14
Insys Therapeutics Enters into Licensing Agreement with Gold Coast Therapeutics 15
Insys Therapeutics Enters into Licensing Agreement with California Pacific Medical Center Research Institute 16
Equity Offering 17
Insys Therapeutics Completes IPO For US$36.8 Million 17
Insys Therapeutics Inc – Key Competitors 19
Insys Therapeutics Inc – Key Employees 20
Insys Therapeutics Inc – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Recent Developments 22
Financial Announcements 22
Nov 05, 2018: INSYS Therapeutics reports third quarter 2018 results 22
Aug 08, 2018: INSYS Therapeutics reports second quarter 2018 results 25
May 08, 2018: INSYS Therapeutics Reports First Quarter 2018 Results 27
Mar 08, 2018: INSYS Therapeutics Reports Fourth Quarter and Full Year 2017 Results 29
Nov 02, 2017: INSYS Therapeutics Reports Third Quarter 2017 Results 30
Aug 03, 2017: Insys Therapeutics Reports Second Quarter 2017 Results 31
May 09, 2017: Insys Therapeutics Reports First Quarter 2017 Results 32
Apr 03, 2017: Insys Therapeutics Reports Fourth Quarter and Year End 2016 Results 33
Corporate Communications 35
Oct 10, 2018: INSYS Therapeutics names new general counsel 35
Aug 09, 2018: INSYS Therapeutics appoints Elizabeth Bohlen to Board of Directors 36
Apr 02, 2018: INSYS Therapeutics Appoints Trudy Vanhove to Board of Directors 37
Feb 01, 2018: INSYS Therapeutics Appoints Vaseem Mahboob to Board of Directors 38
Oct 29, 2017: INSYS Therapeutics Announces Resignation of Patrick P. Fourteau from Board of Directors 39
Oct 29, 2017: INSYS Therapeutics Founder Dr. John N. Kapoor Steps Down from Board of Directors 40
Jul 18, 2017: Insys Therapeutics Appoints Andrew G. Long as Chief Financial Officer 41
May 16, 2017: Insys Therapeutics Announces Chief Financial Officer Transition 42
May 04, 2017: Insys Therapeutics Appoints Rohit Vishnoi to Board of Directors 43
Apr 24, 2017: Dr. Steven James Joins Insys Therapeutics as Vice President of Medical Affairs 44
Mar 27, 2017: Insys Announces Saeed Motahari to Become President and Chief Executive Officer and Member of the Board of Directors Effective April 17, 2017 45
Jan 09, 2017: Insys Therapeutics Announces Retirement of Dr. John N. Kapoor as CEO and Chairman; Appoints Dr. Santosh Vetticaden as Interim CEO and Steven Meyer as Chairman of the Board 46
Legal and Regulatory 47
Aug 22, 2018: Justice Department takes first-of-its-kind-legal action to reduce opioid over-prescription 47
May 15, 2018: INSYS Therapeutics Responds to Unsealing of Previously Filed Qui Tam Complaints and Recaps Transformation Efforts 51
Oct 29, 2017: INSYS Therapeutics to Record a Minimum Liability for Department of Justice Settlement in Q3 2017 52
Product News 53
07/31/2017: Insys Announces Availability of SYNDROS, the First and Only FDA-Approved Liquid Dronabinol, by Prescription 53
05/24/2017: Insys Therapeutics Announces FDA Final Product Label for Syndros 54
Product Approvals 55
Dec 06, 2017: FDA Accepts New Drug Application (NDA) for Buprenorphine Sublingual Spray from INSYS Therapeutics 55
Sep 29, 2017: INSYS Therapeutics Files New Drug Application (NDA) for Buprenorphine Sublingual Spray with FDA 56
Mar 23, 2017: DEA Schedules Insys Therapeutics’ Syndros (dronabinol oral solution) as Schedule II Drug 57
Clinical Trials 58
Dec 07, 2017: INSYS Therapeutics Starts Proof-of-Concept Study of Epinephrine Nasal Spray for Anaphylaxis 58
Other Significant Developments 59
Jun 18, 2018: INSYS Therapeutics Provides an Update on Its Ongoing Transformation 59
Feb 09, 2018: INSYS Therapeutics Addresses Maryland Attorney General’s Motion 60
Appendix 61
Methodology 61
About GlobalData 61
Contact Us 61
Disclaimer 61

List of Tables
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Insys Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Insys Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Insys Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
INSYS Therapeutics Expands Agreement with University of California San Diego 12
INSYS Therapeutics Enters into Licensing Agreement with Lunatus 13
Insys Therapeutics Enters into Licensing Agreement with Senzer 14
Insys Therapeutics Enters into Licensing Agreement with Gold Coast Therapeutics 15
Insys Therapeutics Enters into Licensing Agreement with California Pacific Medical Center Research Institute 16
Insys Therapeutics Completes IPO For US$36.8 Million 17
Insys Therapeutics Inc, Key Competitors 19
Insys Therapeutics Inc, Key Employees 20
Insys Therapeutics Inc, Other Locations 21
Insys Therapeutics Inc, Subsidiaries 21

List of Figures
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Insys Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Insys Therapeutics Inc (INSY):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Bukwang Pharm Co Ltd (003000):製薬・医療:M&Aディール及び事業提携情報
    Summary Bukwang Pharm Co Ltd (Bukwang Pharmaceutical) is a pharmaceutical company that develops new drugs and pharmaceutical products. The company’s products portfolio includes dexid, thioctacid, levovir, legalon, Orfil, azeptin, lonasen, ixel, and asima, among others. Its pipeline products comprise …
  • FirstEnergy Corp:発電所・企業SWOT分析
    FirstEnergy Corp - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (e …
  • Lycatel Services Limited:企業の戦略的SWOT分析
    Lycatel Services Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Debiopharm International SA-医療機器分野:企業M&A・提携分析
    Summary Debiopharm International SA (Debiopharm), a subsidiary of Debiopharm Group is a biopharmaceutical company that develops prescription drugs. The company offers a range of licensing and drug development solutions. It evaluates, searches, and in-licenses promising drug candidates for developmen …
  • Medifast Inc (MED):企業の財務・戦略的SWOT分析
    Medifast Inc (MED) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Health Care Service Corporation:企業の戦略・SWOT・財務分析
    Health Care Service Corporation - Strategy, SWOT and Corporate Finance Report Summary Health Care Service Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (874):企業の財務・戦略的SWOT分析
    Summary Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (Guangzhou Baiyunshan Pharmaceutical) is a manufacturer of herbal medicine, chemical raw material medicine and preparation, biological medicine, and health products. The company also offers herbal tea, Chinese and Western medicine, intermed …
  • CanAlaska Uranium Ltd (CVV):企業の財務・戦略的SWOT分析
    Summary CanAlaska Uranium Ltd (CanAlaska) is a mining and mineral exploration and development company that acquires, explores and develops uranium properties in Athabasca basin of Canada. The company offers projects such as Diamond projects, Cree East project, Fond du Lac project, West McArthur proj …
  • Apetit Oyj:企業の戦略・SWOT・財務情報
    Apetit Oyj - Strategy, SWOT and Corporate Finance Report Summary Apetit Oyj - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Agfa-Gevaert N.V. (AGFB):企業の財務・戦略的SWOT分析
    Agfa-Gevaert N.V. (AGFB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • HTG Molecular Diagnostics Inc (HTGM):企業の財務・戦略的SWOT分析
    Summary HTG Molecular Diagnostics Inc (HTG) is a provider of instruments, reagents, and services for molecular profiling applications. The company's products include HTG edge system, HTG edgeseq reveal software and HTG edgeseq immuno-oncology assay. It develops assays and reagent systems that provid …
  • Tanabe Research Laboratories USA Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Tanabe Research Laboratories USA Inc (Tanabe Research Laboratories USA), a subsidiary of Mitsubishi Tanabe Pharma Corp is a healthcare research center that discovers and develops biological drugs. The laboratory conducts research on metabolics, immunology and inflammation. Its products are u …
  • Array BioPharma Inc (ARRY):製薬・医療:M&Aディール及び事業提携情報
    Summary Array BioPharma Inc (Array) is a biopharmaceutical company, which focuses on the discovery, development and commercialization of targeted small-molecule drugs indicated for the treatment of cancer and inflammatory diseases. The company’s most advanced wholly-owned clinical stage drugs includ …
  • Marathon Petroleum Corporation (MPC)-石油・ガス分野:企業M&A・提携分析
    Summary Marathon Petroleum Corporation (MPC) is a downstream energy company, which refines, markets and transports petroleum products. It owns and operates refineries in the Gulf Coast and Midwest regions of the US. MPC owns common carrier pipeline systems that transport crude oil and refined produc …
  • Snowy Hydro Ltd:企業の戦略的SWOT分析
    Snowy Hydro Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • The Empire District Electric Company:発電所・企業SWOT分析
    The Empire District Electric Company - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information …
  • Castle View International Holdings Limited:企業の戦略・SWOT・財務情報
    Castle View International Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Castle View International Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, …
  • ADDvise Group AB (ADDV A):企業の財務・戦略的SWOT分析
    Summary ADDvise Group AB (ADDvise), formerly ADDvise Lab Solutions AB, is a medical device company that manufactures and markets healthcare and laboratory equipment. The company offers laboratory products such as laboratory equipments, furnishings, safety ventilation, centrifuges, climate chambers, …
  • United Rentals Inc:戦略・SWOT・企業財務分析
    United Rentals Inc - Strategy, SWOT and Corporate Finance Report Summary United Rentals Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Washington University School of Medicine-製薬・医療分野:企業M&A・提携分析
    Summary Washington University School of Medicine (WUSTL), a subsidiary of University of Washington is a medical university that offers patient care, research, education services and neurology clinical trials. The university provides patient care services such as clinical, find a doctor, referring ph …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆